發(fā)布時間：2018-01-18 01:34

  本文關(guān)鍵詞：阿維A與干擾素-α對小鼠淋巴瘤白血病模型的抑制作用　出處：《吉林大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 阿維A 干擾素-α 皮膚T細胞淋巴瘤 IL-6

【摘要】：目的:探討阿維A與干擾素-α聯(lián)合應(yīng)用對小鼠淋巴瘤白血病模型的抑制作用。方法:1.選用C57BL/6純系雄性小鼠,6-8周齡,體重18-22g,鼠T淋巴瘤白血病細胞株EL-4懸浮培養(yǎng)于含20%馬血清的DMEM培養(yǎng)液中常規(guī)培養(yǎng)。待細胞生長至對數(shù)期時,收集細胞,配置成1×107/ml的單細胞懸液。2.取0.1ml接種于C57BL/6小鼠右后肢靠背側(cè)制作動物模型,于接種后第2日開始給藥。3.實驗分組給藥:A組(空白對照組):PBS液0.05ml腹腔注射,PBS液0.1ml灌胃;B組(阿維A高劑量組):PBS液0.05ml腹腔注射,阿維A20mg/kg,0.1ml灌胃;C組(干擾素組):干擾素α-2β0.05ml腹腔注射,PBS液0.1ml灌胃;D組(聯(lián)合用藥組):干擾素α-2β0.05ml腹腔注射,阿維A20mg/kg,0.1ml灌胃;E組(阿維A低劑量組):PBS液0.05ml腹腔注射、阿維A10mg/kg,0.1ml灌胃。4.每日觀察小鼠狀態(tài)以及腫瘤生長情況,從第6天開始,測量腫瘤體積及小鼠重量。接種第14日處死小鼠,剝離腫瘤組織測定腫瘤體積及重量,測定腫瘤抑制率。組織固定、切片、HE染色。ELISA方法測定各組血清IL-6水平。荷瘤小鼠瘤重、腫瘤體積、IL-6細胞因子表達等計量資料用均數(shù)±標準差表示,應(yīng)用SPSS 21.0軟件對數(shù)據(jù)進行統(tǒng)計分析,結(jié)果以x±s表示,各組均值比較用LSD進行方差分析。P0.05為差異有顯著性。結(jié)果:1.小鼠淋巴瘤白血病模型建立,成瘤率100%。2.接種后第7天,藥物抑瘤作用最強,接種后第14天,藥物抑瘤作用降低。阿維A能夠抑制小鼠T細胞淋巴瘤白血病的增殖(p0.05)。干擾素-α可以抑制小鼠T細胞淋巴瘤白血病的增殖,(p0.05)且以干擾素與阿維A聯(lián)合用藥組抑瘤作用最明顯,抑瘤率為51.38%。3.HE染色顯示細胞異常分裂,未發(fā)現(xiàn)腫瘤轉(zhuǎn)移。4.ELISA檢測結(jié)果顯示實驗組較陰性對照組IL-6的濃度稍降低,但無顯著性差異,各實驗組之間濃度無差異。結(jié)論:1.在早期,阿維A和干擾素可以抑制小鼠T細胞淋巴瘤白血病的增殖,并以干擾素-α與阿維A組聯(lián)合應(yīng)用效果明顯。2.干擾素-α、阿維A的抑瘤作用可能與下調(diào)IL-6有關(guān),需要進一步實驗來完善。3.在腫瘤快速生長期,單用阿維A和/或干擾素治療淋巴瘤是不足夠的,需要配合化療或其他。
[Abstract]:Objective: to investigate the inhibitory effect of Avera combined with interferon-偽 (IFN- 偽) on murine lymphoma leukemia model. Methods: 1. C57BL / 6 male mice aged 6-8 weeks were selected. Body weight 18-22 g, murine T lymphoma leukemia cell line EL-4 suspension was cultured in DMEM medium containing 20% horse serum. When the cells grew to logarithmic phase, the cells were collected. A single cell suspension of 1 脳 10 7 / ml. 2. 0.1 ml was inoculated into the right hind limb of C57BL / 6 mice to make animal model. On the 2nd after inoculation, the drug was given to mice in group A (control group: 0. 05 ml, intraperitoneally injected with 0. 1 ml of PBS solution), and the control group was given intraperitoneal injection of 0. 1 ml of PBS solution (n = 0. 05 ml). Group B (Avera high dose group: 0. 05 ml) was injected intraperitoneally and Avera 20 mg / kg 路kg ~ (-1) / ml was intragastrically perfused. Group C (interferon group: interferon 偽 -2 尾 0.05ml intraperitoneally injected with 0.1 ml PBS solution; Group D (group D): interferon 偽 -2 尾 0.05ml was injected intraperitoneally and Avera 20mg / kg ~ (-1) was given intragastrically. Group E (Avera low dose group: 0. 05 ml) was injected intraperitoneally with Avera 10 mg / kg 路ml. 4. The status of mice and tumor growth were observed daily. From the 6th day, the tumor volume and the weight of the mice were measured. The mice were killed on 14th, the tumor volume and weight were determined by stripping the tumor tissue, the tumor inhibition rate, the tissue fixation and the section were determined. The levels of serum IL-6 in each group were determined by HE staining and Elisa. The measurement data of tumor weight and tumor volume IL-6 cytokine expression were expressed as mean 鹵standard deviation. The data were analyzed by SPSS 21.0 software, and the results were expressed as x 鹵s. Results: 1. Mouse lymphoma leukemia model was established, the tumorigenesis rate was 100. 2. 7 days after inoculation. The drug had the strongest inhibitory effect on tumor, and it was 14 days after inoculation. Avera can inhibit the proliferation of murine T-cell lymphoma leukemia. Interferon-偽 can inhibit the proliferation of mouse T-cell lymphoma leukemia. The inhibition rate was 51.38.3.HE staining showed abnormal cell division. No tumor metastasis. 4. Elisa results showed that the concentration of IL-6 in the experimental group was slightly lower than that in the negative control group, but there was no significant difference. Avera and interferon can inhibit the proliferation of murine T-cell lymphoma leukemia, and the combination of interferon- 偽 and avea group has obvious effect .2.Interferon- 偽. The antitumor effect of Avera may be related to down-regulation of IL-6, and further experiments are needed to perfect .3.In the rapid stage of tumor growth, it is not enough to treat lymphoma with avea and / or interferon alone. Need chemotherapy or other.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R733;R-332

【參考文獻】

相關(guān)期刊論文 前6條

1 于凱;王一宇;金仙花;李雪;朱文靜;夏建新;;阿維A與干擾素對人皮膚T細胞淋巴瘤細胞株Hut78細胞增殖及白細胞介素15表達的影響[J];中華皮膚科雜志;2016年11期

2 梁云川;盧會秀;李建英;;阿維A聯(lián)合α-1b干擾素注射液治療頑固多發(fā)性扁平疣療效觀察[J];河北醫(yī)藥;2016年10期

3 張碧紅;張英博;;異維A酸聯(lián)合匹多莫德及重組人干擾素a-2b凝膠治療扁平疣療效觀察[J];中國醫(yī)師雜志;2015年01期

4 吳梅;于長平;田洪青;楊建軍;;阿維A聯(lián)合干擾素治療蕈樣肉芽腫1例[J];中國皮膚性病學(xué)雜志;2006年11期

5 梁彥,魏熙胤,李凱,牛瑞芳,李蘭芳,邱立華;干擾素及三氧化二砷誘導(dǎo)淋巴瘤細胞凋亡及細胞周期阻滯的研究[J];腫瘤防治雜志;2002年02期

6 袁佩光;聯(lián)用骨化三醇和阿維A使皮膚T細胞淋巴瘤得以緩解[J];國外醫(yī)學(xué).皮膚性病學(xué)分冊;1995年06期

相關(guān)碩士學(xué)位論文 前1條

1 黃洋;阿維A聯(lián)合干擾素α及光療對蕈樣肉芽腫的療效及作用機制的研究[D];吉林大學(xué);2016年

，

本文編號：1438895